Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biotech benefits as VC firms raise cash in Q2

This article was originally published in Scrip

Executive Summary

US venture capital firms raised $10.3bn during the second quarter of 2015 – the highest quarterly total since the fourth quarter of 2007, according to the National Venture Capital Association (NVCA) – and roughly $2bn of the newly raised cash may be invested in biotechnology companies.

You may also be interested in...



VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups

Newly renamed Flagship Pioneering has raised a $285m venture capital fund to remain invested in portfolio companies as they grow. Also, 12 new and growing biopharma companies raised $657.15m.

Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role

Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.

Biotech VC Funding Rises As Fewer Companies Get More Dollars

Public company valuations continue to slide as stock market investors shift priorities, but private biotechnology firms are attracting near record-breaking levels of venture capital with one pretty important caveat: More money is being invested in fewer US companies, especially at the earliest stages of business formation.

Related Companies

Latest News
UsernamePublicRestriction

Register

SC029199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel